{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:00:54Z","timestamp":1793826054959,"version":"4.6.1"},"reference-count":21,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100016922","name":"Merck Sharp and Dohme Italia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016922","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Rationale<\/jats:title><jats:p>Doravirine (DOR) is an attractive new option both for ART\u2010na\u00efve people with HIV (PWH) and those with suppressed HIV\u2010RNA who seek treatment simplification. We used real\u2010world data to examine the pattern of use of DOR\u2010containing regimens in these settings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All PWH enrolled in the Icona cohort after January 2020 who initiated a three\u2010drug regimen (3\u2010DR) with DOR or an integrase inhibitor (INSTI)\u2010based regimen as first antiretroviral therapy (ART) or when switching ART, with HIV\u2010RNA \u226450 copies\/mL, were included. We used univariate and multivariable logistic regression models to identify demographic factors, immuno\u2010virological and laboratory markers associated with the prescription of 3\u2010DR DOR instead of INSTI\u2010based regimens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 5803 PWH were included; 1958 were in the first regimen (80 DOR, 1,878 INSTI) and 3854 (387 DOR, 3,458 INSTI) were ART\u2010experienced virologically suppressed. In the first line, 3\u2010DR DOR was more frequently started in people who inject drugs, and its use was also associated with higher body mass index, higher low\u2010density lipoprotein levels, and less advanced HIV disease compared with PWH initiating an INSTI\u2010based regimen. In the switch setting, older age, Italian origin, higher estimated glomerular filtration rate and aspartate aminotransferase levels were all strongly associated with 3\u2010DR DOR use, as well as higher a CD4\/CD8 ratio (only vs. 3\u2010DR INSTI), while the association with lipid abnormalities was attenuated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our analysis shows that among PWH in care in Italy, those with less advanced HIV disease but with other fragilities and potential risk factors for comorbidities are more likely to use DOR\u2010 than INSTI\u2010based regimens, regardless of prior treatment history.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.13740","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T08:50:03Z","timestamp":1733129403000},"page":"489-499","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Predictors for choosing doravirine\u2010based versus <scp>INSTI<\/scp>\u2010based regimen in <scp>ART<\/scp>\u2010na\u00efve and <scp>ART<\/scp>\u2010experienced people with <scp>HIV<\/scp> in real\u2010world setting: Data from the Icona cohort"],"prefix":"10.1111","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0073-1789","authenticated-orcid":false,"given":"Antonella","family":"d'Arminio Monforte","sequence":"first","affiliation":[{"name":"Icona Foundation  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5899-451X","authenticated-orcid":false,"given":"Alessandro","family":"Tavelli","sequence":"additional","affiliation":[{"name":"Icona Foundation  Milan Italy"},{"name":"National PhD Programme in One Health approaches to infectious diseases and life science research, Department of Public Health, Experimental and Forensic Medicine University of Pavia  Pavia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Quiros\u2010Roldan","sequence":"additional","affiliation":[{"name":"Unit of Infection and Tropical Diseases, Department of Clinical and Experimental Sciences University of Brescia and ASST Spedali Civili of Brescia  Brescia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1343-812X","authenticated-orcid":false,"given":"Massimiliano","family":"Fabbiani","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnologies University of Siena  Siena Italy"},{"name":"Infectious and Tropical Diseases Unit Azienda Ospedaliero\u2010Universitaria Senese  Siena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micol","family":"Ferrara","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Unit of Infectious Diseases University of Torino  Torino Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Lo Caputo","sequence":"additional","affiliation":[{"name":"Infection Diseases Unit, Department of Medical and Surgical Sciences University of Foggia  Foggia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Squillace","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Fondazione IRCCS San Gerardo dei Tintori  Monza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0375-9990","authenticated-orcid":false,"given":"Stefano","family":"Rusconi","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Legnano General Hospital, ASST Ovest Milanese &amp; DIBIC University of Milan  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ponzano","sequence":"additional","affiliation":[{"name":"Department of Health Sciences (DISSAL) University of Genoa  Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bovis","sequence":"additional","affiliation":[{"name":"Department of Health Sciences (DISSAL) University of Genoa  Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Antinori","sequence":"additional","affiliation":[{"name":"Clinical and Research Infectious Diseases Department National Institute for Infectious Diseases  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Saracino","sequence":"additional","affiliation":[{"name":"Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Ionian Area University of Bari, Policlinic of Bari  Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6339-919X","authenticated-orcid":false,"given":"Alessandro","family":"Cozzi\u2010Lepri","sequence":"additional","affiliation":[{"name":"Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME) Institute for Global Health  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,2]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103018(19)30336\u20104"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa822"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103018(23)00258\u20108"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002056"},{"key":"e_1_2_10_6_1","unstructured":"EACS HIV Guidelines version 12.0.2023.https:\/\/www.eacsociety.org\/media\/guidelines-12.0.pdf"},{"key":"e_1_2_10_7_1","unstructured":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV n.d.https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/guidelines-adult-adolescent-arv.pdf"},{"key":"e_1_2_10_8_1","unstructured":"Merck Sharp & Dohme LLC.A Phase 3 Randomized Active\u2010Controlled Double\u2010Blind Clinical Study to Evaluate a Switch to Doravirine\/Islatravir (DOR\/ISL 100 mg\/0.25 mg) Once\u2010Daily in Participants With HIV\u20101 Who Are Virologically Suppressed on Bictegravir\/Emtricitabine\/Tenofovir Alafenamide (BIC\/FTC\/TAF).https:\/\/clinicaltrials.gov\/study\/NCT05630755."},{"key":"e_1_2_10_9_1","unstructured":"Merck Sharp & Dohme LLC.A Phase 3 Randomized Active\u2010Controlled Double\u2010Blind Clinical Study to Evaluate the Antiretroviral Activity Safety and Tolerability of Doravirine\/Islatravir (DOR\/ISL 100 mg\/0.25 mg) Once\u2010Daily in HIV\u20101 Infected Treatment\u2010Na\u00efve Participants.https:\/\/clinicaltrials.gov\/study\/NCT05705349."},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00654\u201024"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000029855"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/09564624231195084"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030\u2010200003310\u201000005"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad185"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(24)00150-4"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.2147\/HIV.S184018"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005146"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32833ad8b4"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002730"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1086\/655681"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00326\u201018"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003248"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13740","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T05:37:38Z","timestamp":1741757858000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.13740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,2]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1111\/hiv.13740"],"URL":"https:\/\/doi.org\/10.1111\/hiv.13740","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,2]]},"assertion":[{"value":"2024-08-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}